News

The patent describes a global whole genome amplification methodology using composite DNA/RNA primers able to anneal to multiple sites within the template polynucleotide. The resulting amplified nucleic acid

A Phase I-II safety and efficacy trial is planned for completion by the end of 2008. This study is a randomized, multi-center, investigator-masked, timolol- and placebo-controlled, Phase I-II

Under the terms of the agreement, Cytochroma has granted Mitsubishi Tanabe Pharma (MTPC) an exclusive license to develop, manufacture and commercialize CTA018 in the US and Asia. Cytochroma

In collaboration with Merck & Co, deforolimus is currently being evaluated in multiple clinical trials, both alone and in combination with other therapies, for the treatment of patients

Patient recruitment has now commenced for the trial, with the first patients expected to receive their Biopumps within six weeks. The trial is taking place at the Hadassah

The multi-center, Phase I study of oral IPI-493 is designed as a dose-escalation trial in patients with advanced solid tumors. The primary objectives of the study are to

The stem cell line, called BG01 Olig2-GFP, is engineered to track the Olig2 gene, a neural lineage marker. The Olig2 gene controls a protein that maintains a neural

These agreements also grant to each party license rights and expand the working relationship of the two companies to include development and licensing of future generations of the

The Phase I/II open-label dose ranging study, being conducted with the Prostate Cancer Clinical Trial Consortium, will evaluate the safety, tolerance, pharmacokinetics and potential activity of Apoptone when